Number of Employees: More than 3,000
Marlboro, L&M, Red & White
Welcome to Philip Morris International (PMI) affiliates in Poland. We are the leading tobacco company in the country, manufacturing three of the ten best-selling cigarette brands on the Polish tobacco market. The history of Philip Morris International’s brands in Poland began in 1973 when PMI signed a licensing agreement with Zakłady Przemysłu Tytoniowego w Krakowie (ZPTK) to produce Marlboro. In 1996, PMI acquired from the State Treasury shares of ZPTK and the company was renamed Philip Morris Polska in 1998.
Today we employ more than 3,000 people throughout Poland, in factories and offices in Krakow, Lezajsk, Warsaw and in distribution centers across the country. Over 1,300 employees work at our production facility in Kraków, the history of which dates back to 1876. We have invested over $500 million in improvements of our manufacturing centers and development of our organization and employees over the past several years. That is why now we have one of the most modern PMI factories in Europe.
In 2005, PMI Service Center Europe (PMI SCE) was established in Krakow. It is a service center which provides Finance, Human Resources and Information Services for PMI affiliates in Europe, Middle East and Africa.
It is of utmost importance for us to act with integrity, social responsibility and in compliance with all applicable rules and regulations. We support charitable contributions initiatives to stop domestic violence and various projects to help disabled people.
Smoking and Health
Tobacco products, including cigarettes, are dangerous and addictive. There is overwhelming medical and scientific evidence that smoking causes lung cancer, heart disease, emphysema, and other serious diseases.
All tobacco products are addictive. It can be very difficult to quit smoking, but this should not deter smokers who want to quit from trying to do so.
Public health officials have concluded that secondhand smoke from cigarettes causes serious diseases in non-smokers, including lung cancer and heart disease. We believe the public health conclusions on secondhand smoke are sufficient to support smoking restrictions in public places.
Philip Morris International (PMI) supports comprehensive regulation of tobacco products based on the principle of harm reduction.
To be effective, tobacco regulatory policy must be evidence-based, apply to all tobacco products, and should take into account the views of all legitimate stakeholders including public health authorities, government finance authorities, tobacco manufacturers, and other members of the tobacco supply chain. Regulatory policy must consider the potential to trigger adverse consequences which undermine public health objectives, such as increasing the demand for illicit cigarettes.
While we support comprehensive, effective tobacco regulation, we do not support regulation that prevents adults from buying and using tobacco products or that imposes unnecessary impediments to the operation of the legitimate tobacco market. In that regard, we oppose measures such as generic packaging, point of sale display bans, total bans on communications to adult consumers, and bans on the use of all ingredients in tobacco products.